Animal Vaccines Market - By Animal Type (Farm Animal Vaccines, Companion Animal Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines), By Infections, By Route of Administration & Forecast, 2021-2027

Animal Vaccines Market - By Animal Type (Farm Animal Vaccines, Companion Animal Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines), By Infections, By Route of Administration & Forecast, 2021-2027

Animal Vaccines Market Size

Animal Vaccines Market Size exceeded USD 7.9 billion in 2020 and is anticipated to grow at a CAGR of over 5.8% between 2021 and 2027. Increasing prevalence of foodborne and zoonotic diseases is projected to stimulate the market growth in the coming years. Increasing research and development activities for designing efficient, effective, affordable, and high-quality vaccines for companion and farm animals will benefit the market in the long-term perspective.

To get key market trends

  Download Free Sample

However, lack of well-developed infrastructure & resources for vaccine development and limited expenditure on pet healthcare in emerging countries may negatively impact the animal vaccines market expansion. The absence of an extensive approach to ensure vaccine access in emerging economies leads to increasing inequalities and animal disease burden. The OECD Development Co-operation Report 2020 also highlighted the lack of clinical infrastructure, specific manufacturing processes, and more importantly, the financial resources in the developing world. Moreover, the Animal and Plant Health Inspection Service’s (APHIS) Center for Veterinary Biologics (CVB) regulates veterinary biologics products including animal vaccines. This regulation ensures the purity, safety, potency, and effectiveness of veterinary biologics for its use in the treatment and prevention of animal diseases. Similarly, the European Medicines Agency (EMA) monitors the development and commercialization process of animal vaccines as per the technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). All commercially available animal vaccines undergo a stringent regulatory approval process and are required to meet exhaustive technical requirements.

The COVID-19 pandemic represents an unparalleled public health crisis that has caused unprecedented & enormous disruptions to the global economy affecting multiple industrial sectors. The coronavirus transmits from animal to animal with contact or aerosol transmission, thereby infecting other animals. Numerous incidents have been reported regarding COVID-19 infection in animals. In late 2020, COVID-19 infected farmed minks were reported in multiple countries such as Denmark, Spain, the U.S., Italy, and France among others. Hence, the above developments have promised significant spending on animal health that is further expected to upsurge the business potential. Increasing cases of COVID-19 infections in domestic and wild captive animals will drive the adoption of animal vaccines for ensuring preventive animal health, thereby soaring the industry growth.

Additionally, several organizations are investing in the development of animal vaccines against COVID-19. For instance, Zoetis is developing a vaccine for minks and companion animals. According to the Veterinary and Life Journal of the Russian Federal Veterinary and Phytosanitary, in March 2021, the Carnivak-Cov animal vaccine intended to prevent the spread of SARS-CoV-2 in animals such as dogs, cats, and minks was launched in Russia. Government support in tackling the rising infection cases in animals is poised to benefit the animal vaccines market.

The UK government announced the launch of the UK Animal Vaccine Manufacturing and Innovation Centre in Surrey, intending to accelerate the vaccine development for livestock and to curb the spread of viral diseases including coronavirus. As a result, the increasing COVID-19 infection cases in animals, research initiatives adopted by the private players, and government support will facilitate the industry expansion significantly.

What are the growth opportunities in this market?

 Download Free Sample

Growing pet adoption is slated to amplify the business growth

The adoption of companion animals has significantly increased in recent years. Pets are considered a part of the family and perfect companions for senior citizens. Rising pet adoption will increase the demand for animal vaccines, thereby fuelling the market progression. The pet adoption rates increased dramatically with the onset of the COVID-19 pandemic. According to the Shelter Animals Count data, in 2020, the number of pet adoptions in the U.S. surged significantly with approximately 26,000 more pet adoptions than in 2019. As per the COVID-19 Impact Report, in 2020, the national pet adoption rate soared by 34% as compared to 2019. A similar trend was observed in Italy, in 2020, with approximately 3.5 million Italians reportedly adopting a pet after the first lockdown.

Animal Vaccines Market Analysis

The farm animal vaccines market was valued at USD 5.49 billion in 2020 led by the increasing prevalence of zoonoses among farm animals. Several zoonoses such as leptospirosis, Johne’s Diseases (JD), viral respiratory tract infections, bovine ephemeral fever, and infectious bovine rhinotracheitis (IBR) among others affect farm animals worldwide and increase the disease burden. Rising prevalence of these conditions is predicted to augment the demand for animal vaccines, thereby stimulating the industry progression during the forecast timeframe.

The live attenuated vaccines segment accounted for around 44% of the market share in 2020 impelled by the high clinical efficacy as compared to inactivated vaccines. Majority of the commercially available veterinary vaccines are live attenuated vaccines. These vaccines are capable of inducing humoral as well as cell-mediated immune responses, thereby offering long-term effectivity. These vaccines are also known to induce higher immunogenicity and often, a single vaccine dose is sufficient to provide long-term protection. Live attenuated vaccines are highly preferred in emerging economies owing to high cost-effectivity as compared to other vaccines.

The viral vaccines segment will reach USD 6.34 billion by 2027 due to the growing prevalence of viral infections globally. The rising demand for meat has led to intense production, with livestock farms housing animals in high densities that prove conducive to rapid pathogen transmission and result in endemic infectious diseases. According to the World Organization for Animal Health (OIE), from 2016 to 2020, notable increase in African swine fever (ASF) outbreaks were reported in African, European, and Asian region. The viral disease was present in 60 countries and accounted for 8,202,702 swine deaths. In the first five months of 2021, the authorities in Poland reported an exponential 520% increase in ASF outbreaks in domestic pig herds. The constant threat posed by the endemic and emerging viral disease has led to the development of viral vaccines offering clinical effectiveness.

Learn more about the key segments shaping this market

 Download Free Sample

The injection vaccines segment captured USD 4.57 billion in 2020. Intramuscular or subcutaneous is the dominant route of vaccine administration in animals and is prioritized for diseases requiring systemic immunity. This approach optimizes the vaccine immunogenicity and reduces potential adverse reactions at the injection site. Several clinical studies have showcased the immunological benefit of injectable vaccines with minimal local side effects. Administering vaccine through injection also helps in ensuring the appropriate dosage. The development of novel mRNA vaccines that are administrated using the intramuscular approach has aided in driving clinical efficacy. Multiple studies have reported that vaccines administered through injections offer better efficiency and high humoral & cellular immune responses with a comparatively long duration of effect.

Learn more about the key segments shaping this market

 Download Free Sample

U.S. dominated the North America animal vaccines market and will cross USD 4.20 billion by 2027 on account of the several factors such as growing acceptance of pets, high pet care expenditure, and a rise in the incidence of zoonotic diseases across the country. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, there were more than 89 million pet dogs and 94 million pet cats in the U.S. households. The veterinary care expenditure surged from USD 48.35 billion in 2010 to USD 75.38 billion in 2019 and is unparalleled as compared to the other countries. The growing pet adoption and high pet care expenditure are set to increase the demand for animal vaccines, further facilitating the industry revenue.

Animal Vaccines Market Share

Some of the major companies operating in the market are

• Ceva Sante Animale
• Boehringer Ingelheim Animal Health
• Dechra Pharmaceuticals
• Elanco Animal Health
• Merck Animal Health
• Hipra Animal Health Limited
• Zoetis
• Neogen Corporation

These major leaders emphasize on adopting strategic formulations such as research collaborations, vertical integration, new product development & commercialization for business expansion. Furthermore, these participants are expanding their geographical presence to untapped geographies that allows them to enter new markets and garner maximum revenue share.

Animal vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments

Click here to Buy Section of this Report

Market, By Animal type, 2016 - 2027 (USD Million)

• Farm Animal Vaccines
  • Poultry Vaccines
  • Cattle Vaccines
  • Swine Vaccines
  • Equine Vaccines
  • Aquaculture Vaccines
• Companion Animal Vaccines
  • Dog Vaccines
  • Cat Vaccines

Market, By Technology, 2016 - 2027 (USD Million)

• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Other Vaccines

Market, By Infections, 2016 - 2027 (USD Million)

• Bacterial Vaccines
• Viral Vaccines
• Parasitic Vaccines
• Fungal Vaccines
• Others

Market, By Route of Administration, 2016 - 2027 (USD Million)

• Injection Vaccines
• Oral Vaccines
• Immersion/Spray Vaccines
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Taiwan
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • GCC Countries
  • Israel